Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
I
344860
vs
K
KOSPI 200
Over the past 12 months, InnoGene Co Ltd has underperformed KOSPI 200, delivering a return of -8% compared to KOSPI 200's +53% growth.
Stocks Performance
344860 vs KOSPI 200
Performance Gap
344860 vs KOSPI 200
Performance By Year
344860 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
InnoGene Co Ltd
Glance View
InnoGene Co Ltd makes genetic and molecular diagnostic products used to detect diseases from biological samples. Its business centers on test kits and related reagents that labs, hospitals, and medical testing organizations use to identify infections, screen for conditions, or support clinical decisions. It also earns money from supplying consumables and related assay products that customers need to run tests repeatedly. The company sells mainly to medical laboratories, hospitals, and other healthcare providers rather than to ordinary consumers. Those customers buy InnoGene’s products because they need reliable tests that can be run in-house or in specialized diagnostic settings. This makes the company part of the healthcare tools supply chain, sitting between research, test development, and day-to-day medical testing. What sets this kind of business apart is that demand depends on the need for accurate, standardized testing rather than on one-time hardware sales alone. Once a lab adopts a diagnostic method, it often keeps buying the matching reagents and kits, which can create repeat business. InnoGene’s role is to package complex genetic testing into products that labs can use consistently and efficiently.